Context: Gestational diabetes mellitus (GDM) is associated with disturbances in maternal lipid metabolism. Hypertriacylglycerolemia in GDM is associated with an increased risk of large for gestational age neonates, but the pathogenesis of disrupted lipid homeostasis remains unclear.
G estational diabetes mellitus (GDM) is defined as a state of glucose intolerance of varying severity with the onset of first recognition during pregnancy (1) and is one of the most commonly observed pregnancy complications, affecting about 7% of all pregnancies (2) , and the prevalence of GDM is 2.4 times higher using the most recent criteria (3) . GDM is associated with numerous and serious short-and long-term complications for both mother and fetus (4) . Women with GDM have a greater risk of developing hypertensive disorders of pregnancy such as preeclampsia (5) , and approximately 50% of women with a history of GDM develop type 2 diabetes mellitus within 5 to 10 years after delivery (6) . Children of mothers with GDM are more likely to be macrosomic and have higher body fat at birth as well as have an elevated risk of obesity, cardiovascular disease, and diabetes later in life (5) . However, the mechanisms underlying the pathophysiology of GDM and its adverse effects on the mother and child remain poorly understood. Evidence from clinical and experimental studies indicated that maternal adipose tissue dysfunction, characterized by increased lipolysis and abnormal production of adipokines (7), adversely affects the quality and quantity of lipids transferred to the fetus. Adipose tissue dysfunction is associated with an increased risk of having large for gestational age babies and is a stronger predictor of fetal overgrowth than glucose levels (8) . These findings imply that impaired maternal lipid metabolism has profound and detrimental effects on fetal adiposity and growth, but a detailed understanding of the precise mechanism for impaired lipid homeostasis in GDM remains to be established.
Adrenomedullin (AM) is a potent vasodilator peptide with 52-amino acid residues originally isolated from human pheochromocytoma (9) . AM is a member of the calcitonin peptide superfamily, and its signal is mediated by calcitonin receptor-like receptor (CRLR). CRLR interacts with receptor activity-modifying proteins (RAMPs), among which RAMP2 and RAMP3 carry CRLR from the endoplasmic reticulum to the cellular membrane to confer high affinity for AM (10) . AM is expressed by and secreted from a variety of cell types, can function in an autocrine/paracrine fashion (11) , and is considered to have pleiotropic effects, including cell growth (12) , inflammation (13) , hormone secretion (14) , pregnancy-related vascular adaptations (15) , and fetal growth (16) . Recent studies in the rat show that AM and its receptors are expressed in adipose tissue (17) ; administration of AM induces hyperglycemia, which can be reversed by an AM-neutralizing antibody; and AM increases cyclic adenosine monophosphate (cAMP) levels and lipolysis in adipocytes (18) . In humans, plasma AM concentrations are elevated in obese individuals (19) and patients with type 2 diabetes mellitus (13) . AM concentrations are also increased in amniotic fluid from diabetic pregnancies compared with controls (20) . Taken together, these reports indicate that AM and its receptors are present in adipose tissue, and AM maybe involved in the pathogenesis of insulin resistance in GDM as observed in diabetes. Therefore, we proposed that in addition to its known vasodilatory properties, excessive AM production by adipose tissue might have actions against lipogenesis, hence adversely affecting the quantity and quality of lipids available in the maternal circulation for transfer to the fetus, leading to the fetal excessive adiposity and overgrowth. These include opposing the actions of insulin and mediating the actions of tumor necrosis factor (TNF)-a. Thus, the manipulation of AM and its effects in adipose tissues may represent a novel approach in reducing the risk of GDM and fetal overgrowth.
Materials and Methods

Subjects
This study was approved by Baylor College of Medicine Institutional Review Board (IRB H28527) and was conducted according to Declaration of Helsinki principles. Informed consents were obtained from all participating subjects admitted to the Pavillion for Women at Texas Children's Hospital who were scheduled for elective nonlaboring cesarean section for the delivery at term. Omental adipose tissues were obtained in term pregnancy from women with normal glucose tolerance (NGT, n = 10) and GDM (n = 10) during caesarian sections between August 2014 and February 2017. All women were screened for GDM, and patients in the NGT group had negative screening results. The 1-hour glucose screen cutoff for GDM is 140 mg/dL. The 3-hour glucose tolerance test values are fasting .95 mg/dL, 1 hour .180 mg/dL, 2 hours .155 mg/dL, and 3 hours .140 mg/dL. Pregnant patients were excluded from participating in the study if they had preexisting diabetes, fetal anomalies, multifetal pregnancy, hypertension, preeclampsia, immunosuppressive treatment, or clinical evidence of maternal or fetal infection. Prepregnancy/early pregnancy height and weight from each subject were obtained from the records, and body mass index (BMI) was calculated based on the recorded height and the weight, measured at the first visit during early pregnancy or selfreported as prepregnancy weight. The relevant clinical details of the subjects are shown in Table 1 .
Adipose tissue explant culture
Adipose tissues were finely diced and transferred to wells of 24-well plates containing Dulbecco's modified Eagle medium (Gibco, Life Technologies, Gaithersburg, MD) and cultured in a humidified atmosphere of 21% O 2 and 5% CO 2 at 37°C overnight (21) . After refreshing the medium, the tissues were incubated in the presence or absence of AM (1, 10, and 100 nM; American Peptide Co., Sunnyvale, CA), AM antagonist AM22-52 (1 mM; American Peptide Co., Sunnyvale, CA), or insulin (100 nM; Sigma-Aldrich, St. Louis, MO) for different combinations, and tissues were collected at assigned time schedules.
Quantitative real-time polymerase chain reaction Total RNA was isolated from adipose tissues using TRIzol (Life Technologies, Grand Island, NY), and reverse transcription was performed as previously described (22) . Quantitative realtime polymerase chain reaction (PCR) was performed using TaqMan probes for AM, CRLR, RAMP2, and RAMP3 (Life Technologies). Amplification of housekeeping GAPDH (forward primer: 5 0 -GGTCTCCTCTGACTTCAACA-3 0 ; reverse primer: 5 0 -AGCCAAATTCGTTGTCATAC-3 0 ) served as an endogenous control. PCR conditions for TaqMan gene expression were 2 minutes at 50°C and 10 minutes at 95°C for 1 cycle, then 15 seconds at 95°C and 1 minute at 60°C for 40 cycles. All experiments were performed in triplicate. Results were calculated using the 2-DDCT method and expressed in folds increase/ decrease of the gene of interest.
Immunofluorescent imaging analysis
Optimal cutting temperature medium embedded tissues were cut at 5-to 7-mm thickness and mounted on gelatin-coated slides. The sections were fixed with methanol and acetone mixture (1:1) and blocked with 10% donkey serum in phosphate-buffered saline, and then the first primary antibody, goat polyclonal CRLR antibody (Santa Cruz Biotechnology, Dallas, TX), and rabbit RAMP2 and RAMP3 polyclonal antibodies (23) were applied at 1:100 dilution, followed by donkey anti-goat Alexa Flour 594/anti-rabbit IgG TRITC (Life Technologies). Slides were then mounted with Mounting medium (Dako, Carpinteria, CA) containing 4 0 ,6-diamidino-2-phenylindole (Vector Laboratories, Burlingame, CA) and viewed under an Olympus BX51 microscope. The intensity was measured by using CellSence software (Olympus Scientific, Waltham, MA).
Human preadipocyte culture and lipolysis assessment
Primary human preadipocytes (ATCC PCS-210-010) were differentiated into mature adipocytes in wells of 24-well plates containing adipocyte differentiation medium (Cell Applications, San Diego, CA) in a 5% CO 2 atmosphere at 37°C and treated with AM (1 nM, 10 nM, and 100 nM), with or without AM22-52 (1 mM). In some experiments, cells were treated with glucose (1 to 4 mg/mL; Sigma-Aldrich, St. Louis, MO), TNF-a (0 to 1.0 ng/mL; Sigma-Aldrich), insulin (100 nM; SigmaAldrich), or the inhibitors of protein kinase B (Akt) (LY294002, 10 mM; Sigma-Aldrich), extracellular signalrelated kinase (ERK) (PD98059, 10 mM; Sigma-Aldrich), or protein kinase A (PKA) pathway (H-89, 10 mM; SigmaAldrich). The glycerol release into cell culture medium was assessed by using Free Glycerol Reagent (Sigma-Aldrich) per the manufacturer's instruction. The absorbance at A540 were read and recorded by using Spectrophotometer CLARIO STAR (BMG Labtech, Ortenberg, Germany).
Western blotting
Western blotting was performed as described previously (24) . Briefly, equal amounts of proteins were separated by polyacrylamide gel electrophoresis and then were electrotransferred to polyvinylidene difluoride membranes. Membranes were blocked with 5% fat-free milk in tris-buffered saline with 0.1% Tween 20 and were incubated with primary antibodies for adiponectin (abcam, Cambridge, MA), leptin (abcam), resistin (abcam), phospho-insulin receptor (IR)-b or total IR-b (Cell Signaling), phospho-insulin receptor substrate (IRS)-1 or total IRS-1 (Cell Signaling, Beverly, MA), and b-actin (abcam) overnight at 4°C. After washing, the membranes were incubated with horseradish peroxidase (HRP)-conjugated anti-rabbit or anti-mouse secondary antibody (Southern Biotech, Birmingham, AL). Target proteins were visualized with Pierce enhanced chemiluminescence detection (Thermo Scientific, Houston, TX). The signals were quantified by using Odyssey Imaging System (LI-COR Biosciences, Lincoln, NE).
Statistics
All data are presented as mean 6 standard error of the mean. Data were calculated and analyzed by GraphPad Prism (GraphPad Software, La Jolla, CA). Repeated-measures analysis of variance (treatment and time as factors) with a Bonferroni post hoc test was used for comparisons between groups. Messenger RNA (mRNA) and protein expressions were compared between control and treatment groups using the unpaired Student t test. Statistical significance was defined as P , 0.05.
Results
Omental adipose tissues were obtained from women at term at the time of scheduled cesarean section. The demographic data of participants in this study are summarized in Table 1 . There were eight non-Hispanic and two Hispanic women in the NGT group and six nonHispanic and four Hispanic women in the GDM group. There were no significant differences in maternal age, gestational age, birth weight, prepregnancy/early pregnancy BMI, and fasting blood glucose between NGT and GDM patients (P . 0.05). Seven of 10 women with GDM were prescribed insulin in addition to dietary management. The glucose levels presented are fasting levels, and all were obtained at term and similar to that in NGT. The glucose levels in NGT were also of the fasting levels obtained at term (n = 5) and during the second trimester (n = 5).
GDM is associated with increased AM and its receptor expression in adipose tissues
AM mRNA expression, quantified by real-time PCR, was significantly higher in adipose tissue from GDM compared with NGT women [ Fig. 1(a) , P , 0.01]. Furthermore, the mRNA expression for AM receptor components CRLR, RAMP2, and RAMP3 was also significantly elevated in adipose tissue in GDM compared with NGT women (P , 0.01). Immunofluorescent staining indicated that AM receptor components CRLR, RAMP2, and RAMP3 were expressed on adipocytes [ Fig. 1(b) ], and their expressions were also significantly Values are expressed as mean 6 standard error unless otherwise indicated.
doi: 10.1210/jc.2017-00920 https://academic.oup.com/jcem Figure 1 . Expression of AM and its receptor components in human adipose tissue. (a) The mRNA levels of AM, CRLR, RAMP2, and RAMP3 in adipose tissue from pregnant women with NGT (n = 10) and GDM (n = 10) measured using real-Time PCR. AM, CRLR, RAMP2, and RAMP3 mRNA were normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA expression. (b) The immunofluorescent localization of CRLR, RAMP2, and RAMP3 in human adipose tissue. Presence of CRLR, RAMP2, and RAMP3 (red) in the sections of human adipose tissue from NGT and GDM women were determined by immunofluorescent staining with specific antibodies. Relative intensities were normalized to the number of nuclei. Adipocyte nucleus (blue) was identified by 4 0 ,6-diamidino-2-phenylindole. Original magnification, 3200. The average intensity was obtained for each specimen from five separate fields each containing approximately 30 cells, with a total of about 150 cells per specimen, and final data are displayed as mean 6 standard error of the mean from six women in each group. Different letters at the top of the bars indicate significant differences between groups (P , 0.01).
increased in GDM compared with uncomplicated patients (P , 0.01).
GDM is associated with abnormal adipokine protein expression in adipose tissue
Western blots were performed to evaluate differences in adipokine levels between NGT and GDM women. As shown in Fig. 2 , adiponectin, leptin, and resistin were expressed in adipose tissues from NGT and GDM women. Densitometry analysis revealed that the expression of adiponectin in adipose tissue was significantly lower in GDM compared with NGT women (P , 0.01). In contrast, the expressions of leptin and resistin were substantially higher in GDM compared with NGT patients (P , 0.01), suggesting that GDM women have abnormal adipokine expressions in adipose tissue.
Glucose and TNF-a stimulate mRNA for AM and its receptor components in adipose tissue explants
Increases in glucose concentrations from 1 mg/mL to 4 mg/mL resulted in a dose-dependent stimulation in AM mRNA expression in adipose tissue explants [ Fig. 3(a) , P , 0.05]. The mRNA expressions for CRLR, RAMP2, and RAMP3 were also significantly increased when treated with increasing doses of glucose. Furthermore, TNF-a significantly increased AM mRNA expression in a dose-dependent manner [ Fig. 3(b) , P , 0.05]. In addition, TNF-a dose-dependently elevated mRNA expressions for CRLR, RAMP2, and RAMP3 in adipose tissue (P , 0.05), indicating that increased glucose and cytokines in GDM may contribute, at least in part, to the enhanced AM and its receptor expression.
AM stimulates lipolysis
Treatment with AM for 24 hours dose-dependently increased glycerol levels in the culture medium of human adipocytes [ Fig. 4(a) , P , 0.05]. Treatment with AM at the concentration of 100 nM time-dependently increased glycerol levels in the medium. The increases in glycerol release were significantly reduced by preincubation with AM antagonist AM22-52 (1 mM) and ERK inhibitor PD98059 (10 mM, P , 0.05) but not by Akt inhibitor LY294002 (10 mM, P . 0.05) or PKA inhibitor H-89 (10 mM, P . 0.05). In addition, treatment with insulin at Figure 2 . Western immunoblotting of adiponectin, leptin, and resistin proteins in human adipose tissue. Representative blots of (a) adiponectin, (b) leptin, and (c) resistin in adipose tissue from groups of NGT and GDM are shown. Relative densities of (d) adiponectin, (e) leptin, and (f) resistin to b-actin were calculated and compared between groups (n = 10). Data are displayed as mean 6 standard error of the mean. Different letters at the top of the bars indicate significant differences between groups (P , 0.01).
10 nM for 5 or 10 minutes substantially inhibited AMinduced glycerol production, whereas this inhibition was completely abolished 1 hour after AM treatment. Furthermore, TNF-a-induced lipolysis was significantly inhibited by AM antagonist AM22-52. These results indicate that AM stimulates lipolysis, and the effects are rapid and reversible by AM antagonist.
AM inhibits the phosphorylation of IR-b and IRS-1 but stimulates leptin and resistin expressions
Western blotting demonstrated that AM caused a significant inhibition of the phosphorylation of IR-b in a dose-dependent manner [ Fig. 4(b) , P , 0.05]. In addition, AM time-dependently inhibited phosphorylation of IRS-1 (P , 0.05), implying that AM can inhibit the insulin signaling cascade and may play a role in insulin resistance. AM did not significantly affect adiponectin protein expression in adipose tissue explant (Fig. 5, P . 0.05), but AM significantly stimulated leptin (P , 0.05) and resistin expression (P , 0.05). In addition, AM antagonist AM22-52, but not insulin, significantly reversed AM-induced leptin and resistin expressions (P , 0.05), indicating that AM effects on these adipokines are mediated through its specific receptors. Furthermore, quantitative PCR analysis shown that the increased mRNA expression of leptin and resistin in adipose tissue from GDM was reduced by AM22-52 treatment (1 mM, 24 hours), implying that AM-mediated leptin and resistin overexpression in adipose tissue from GDM women could be abolished by AM antagonist.
Discussion
In this study, we investigated the role of AM in lipid metabolism in normal pregnancy and its possible involvement in the development of GDM. We present the novel findings that mRNA for AM and its receptor components CRLR, RAMP2, and RAMP3 are expressed in omental adipose tissue and their levels are higher in GDM compared with NGT women. Glucose and TNF-a dose-dependently increased AM and its receptor components in adipose tissue explants from NGT women. In addition, AM stimulated lipolysis in human adipocytes in vitro in a dose-and time-dependent manner, and AM disrupted insulin-inhibited glycerol production by adipocytes. AM1 receptor antagonist AM 22-52 blocked both AM-and TNF-a-induced lipolysis. AM inhibited the levels of phospho-IR-b and phospho-IRS-1, as well as enhanced leptin and resistin expressions, and increased mRNA expression of leptin and resistin in adipose tissue from GDM was reduced by AM22-52 treatment. Our data suggest that increased AM action through the elevated expression of AM and its receptor components in adipose tissue alters lipid metabolism in pregnancy, thus inducing dyslipidemia and contributing to the Figure 3 . The effect of glucose and TNF-a on mRNA for AM, CRLR, RAMP2, and RAMP3 in human adipose tissue. Adipose tissue from NGT women (n = 10) was incubated with increasing doses of (a) glucose (1 to 4 mg/mL) or (b) TNF-a (0 to 1 ng/mL) for 24 hours, and the mRNA expressions for AM, CRLR, RAMP2, and RAMP3 were determined using real-time PCR and analyzed by GraphPad Prism. Data are displayed as mean 6 standard error of the mean. Different letters at the top of the bars indicate significant differences between groups (P , 0.05). GAPDH, glyceraldehyde 3-phosphate dehydrogenase. development of GDM. Therefore, we propose that blockage of AM action with AM antagonist may reverse its adverse effects on maternal lipid metabolism and thus offer a way of normalizing disturbed lipid homeostasis in pregnancy complicated by diabetes.
The clinical characteristics of GDM patients in this study (Table 1) were similar to that reported in other studies showing a trend of greater fetal birth weight in GDM compared with NGT women (25) (26) (27) . Because these subjects were all delivered by elective cesarean sections, there were no significant differences in the gestational length between NGT and GDM groups. The differences in BMI between GDM and NGT women were also not significant and therefore suggest that the changes in AM and its receptor component expressions, as well as its effects on lipid metabolism in GDM, may not be related to adipose tissue mass.
Plasma AM concentrations are elevated in patients with type 2 diabetes mellitus (13), as well as amniotic fluid from diabetic pregnancies compared with uncomplicated pregnancies (20) , suggesting possible involvement of AM in the pathogenesis of insulin resistance seen in diabetes. Irrespective of the AM levels in circulation, elevations in the AM and its receptor components Figure 5 . The influence of AM and/or its antagonist, AM22-52, on adipokines in human adipose tissue. (a-f) Adipose tissue from NGT women was incubated with AM at doses indicated for 24 hours. Equivalent amounts of proteins were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis, and Western blottings were performed. The representative blots for (a) adiponectin (Adpn), (b) leptin, and (c) resistin are shown. Density of specific bands for (d) Adpn, (e) leptin, and (f) resistin is expressed as a ratio to that of b-actin from adipose tissues of six NGT women. (g) The mRNA levels of Adpn, leptin, and resistin in adipose tissues from six women in each of NGT and GDM with or without AM22-52 (1 mM for 24 hours) treatment, using real-time PCR. mRNA for Adpn, leptin, and resistin was normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA expression. Different letters at the top of the bars indicate significant differences between groups (P , 0.05). in adipose tissue locally could alter lipid metabolism. The current study showed that mRNA expressions for AM and its receptor components CRLR, RAMP2, and RAMP3 are significantly higher in omental adipose tissues from GDM patients compared with NGT pregnancies [ Fig. 1(a)] , with similar BMIs. The immunofluorescent staining analysis indicated significant increases in protein expression of CRLR, RAMP2, and RAMP3 [ Fig. 1(b) ] in adipocytes in patients with GDM compared with NGT women, suggesting a consistent enhancement in both AM and its receptor components in adipose tissues from GDM patients. Thus, we propose that AM secreted by adipose tissue may influence the lipid homeostasis through elevated receptors on adipocytes in an endocrine and paracrine manner.
Adipose tissue has been recognized as more than simply a storage depot for lipids and indeed acts as a highly active organ that secretes endocrine, paracrine, and autocrine proteins, called adipokines (28) . Adiponectin is an insulin-sensitizing adipokine synthesized by adipocytes (29) . It stimulates glucose uptake in skeletal muscle and reduces hepatic glucose production through adenosine 5 0 -monophosphate-activated protein kinase. Leptin is produced mainly by adipocytes and plays a key role in the regulation of energy intake and expenditure (30) . Another adipokine, resistin, is a signaling molecule in adipocytes. It impairs glucose tolerance by inducing insulin resistance (29) . The current study confirms that the expression of adiponectin in adipose tissue was significantly reduced in GDM compared with NGT pregnancies (Fig. 2) . In contrast, the expressions of leptin and resistin in adipose tissue were substantially increased in GDM patients compared with NGT, suggesting abnormal adipokine levels in GDM. Although AM had no significant effects on adiponectin expression, it significantly stimulated leptin and resistin expressions in explants of adipose tissue from NGT women (Fig. 5) . AM1 receptor antagonist AM22-52 significantly reversed AMinduced leptin and resistin expressions, and the increased mRNA expression of leptin and resistin in adipose tissue from GDM was reduced by AM22-52 treatment (Fig. 5) . These results suggest that AM may play a critical role in stimulating adipocyte leptin and resistin productions, which favor insulin resistance, and, more important, the adverse effects of leptin and resistin could be reduced by AM antagonist. It is unclear from these studies the downstream signaling events of AM enhancing the transcription of leptin and resistin. However, because AM22-52 can reverse AM actions, RAMP2 association with CRLR (AM1 receptor) may be the primary receptor for AM effects in this tissue, as the inhibitory effects of AM22-52 do not involve RAMP3 (15) , and AM actions through RAMP3 (AM2 receptor) are primarily reversed by calcitonin gene-related peptide (CGRP) 8-37. Further studies are required to fully determine the specific downstream signaling molecules involved in AM-induced upregulation of leptin and resistin.
Next, we examined whether increased glucose levels regulate expression of AM and its receptors in adipose tissue explants. Glucose dose-dependently increased mRNA expressions of both AM and its receptor components CRLR, RAMP2, and RAMP3 [ Fig. 3(a) ]. These findings provide new insight into the relationship between hyperglycemia and elevated circulating AM levels in diabetic patients. Hyperglycemia itself in GDM may be one of the stimulants for the elevated AM and its receptor expressions in adipocytes, thus contributing to the disturbed lipid metabolism by enhancing AM's action. Because most of the GDM subjects were on insulin treatment, and the fasting glucose levels were similar to that of NGT subjects, it is unclear what role glucose may play in stimulating AM and its receptors in these insulintreated GDM subjects, therefore limiting the interpretation of our results. The fasting glucose levels measured at term in GDM subjects receiving insulin may not provide an accurate picture of glucose dynamics, and in these subjects, elevated glucose levels during earlier stages of gestation could provide stimulus for upregulated AM in the adipose tissue. It is also possible that the AM and its receptor regulations in the adipose tissue from GDM subjects may be more sensitive to glucose. On the other hand, TNF-a is a cytokine largely expressed in adipose tissue in diabetes mellitus (31) , which may be associated with impaired insulin sensitivity in GDM. Here we showed that TNF-a dose-dependently increased mRNA for both AM [ Fig. 3(b) ] and its receptor components CRLR, RAMP2, and RAMP3 in the adipose tissue. Thus, we propose that increased circulating TNF-a levels in GDM patients may further increase AM and its receptor levels in adipose tissue and additively boost glucose actions on the AM system.
In normal pregnancy, alterations in lipid metabolism promote the accumulation of maternal fat stores in early and midpregnancy and enhance fat mobilization in late pregnancy (8) . GDM is accompanied by alterations in fasting and postprandial plasma concentrations of lipids, including an increase in plasma concentrations of triacylglycerol, free fatty acids, and delayed postprandial clearance of fatty acids (32) . Increased circulating free fatty acids have also been associated with fetal overgrowth, particularly of adipose tissue (33) , suggesting that neonatal birth weight was positively correlated with concentrations of triacylglycerol and free fatty acids. By measuring the glycerol production, the breakdown product of triglycerides, we demonstrated that AM induces lipolysis in human adipocytes [ Fig. 4(a) ], and this effect was dose-and time-dependent. The lipolytic effects of AM were unabated even in the presence of proadipogenic insulin. AM effects were reduced in the presence of its antagonist, AM22-52 [ Fig. 4(a) ], indicating the specificity of AM effects. Moreover, TNF-a-induced lipolysis was also significantly inhibited by AM antagonist [ Fig. 4(a) ], perhaps due to its blockade of the actions of AM stimulated by TNF-a. It is apparent that excessive AM induces a state of dyslipidemia consistent with insulin resistance seen in GDM, and the alteration in lipid profile on the maternal side would affect the quantity and/or the quality of lipids being transferred to the fetus, leading to fetal macrosomia.
The outcome of GDM pregnancy depends on the complex physiologic system that includes not only the maternal metabolic component but also placental and fetal components. Maternal lipids are abnormal in GDM pregnancies, and these lipid abnormalities are associated with poorer maternal and fetal health. Studies examining lipids in women with GDM report a deviation from the usual patterns of pregnancy-associated changes in maternal lipids, including changes in lipoproteins and differences in the triglyceride, cholesterol, or apolipoprotein content of the maternal lipoproteins (8) . It is possible that AM-related mechanisms in adipose tissues may underlie some of the mechanisms responsible for these changes in lipids in GDM. Because our study is restricted to just the maternal component of this complex physiologic system, it is unknown if AM and its receptor system could also modulate placental functions and fetal growth and/or adiposity components. Our study indicates a possible beneficial effect of AM antagonist to control abnormal maternal lipid metabolism.
The intracellular mechanisms responsible for insulin suppression of lipolysis involve activation of IR-b and the insulin receptor protein tyrosine kinase, which phosphorylates the intracellular insulin receptor substrates, mainly IRS-1 (34, 35) . Our results shows that AM inhibits the phosphorylation of IR-b and IRS-1 [ Fig. 4(b) ] in adipose tissue explants, suggesting that AM interferes with insulin action by reducing signaling downstream of the insulin receptors and consequently impairing biological actions of insulin on lipid metabolism.
Both cAMP-dependent and cAMP-independent pathways have been suggested to mediate lipolysis (36) . In the cAMP-dependent pathway, activated adenylyl cyclase produces cAMP, which activates PKA and subsequently triggers lipolysis (37) . In the cAMP-independent pathways, an increase in protein kinase C activates ERK1/2 and induces triglyceride breakdown (38) . In our study, an inhibitor of mitogen-activated protein kinase and ERK, PD98059, blocked AM-induced lipolysis in adipocytes in culture [ Fig. 4(a) ], suggesting that AM-induced lipolysis is mediated through a cAMP-independent protein kinase C-mitogen-activated protein kinase/ERK pathway. Lack of inhibitory effects of LY294002, an inhibitor of Akt, and H-89, an inhibitor of PKA, on AM-induced lipolysis [ Fig. 4(a) ] indicates that Akt and cAMP-dependent PKA pathways may not be involved in this process.
The actions of AM are mediated by two subtypes, AM1 receptor (CRLR + RAMP2) and AM2 receptor (CRLR + RAMP3). In the primary adipocyte cultures, AM-induced lipolysis was reported to be blocked by both AM1 receptor antagonist AM22-52 and AM2 receptor antagonist CGRP 8-37 (39) . Although we have not tested the effectiveness of CGRP 8-37 in blocking AM actions in our studies, all of the effects of AM and AM22-52 in the adipose tissue from NGT and GDM appear to suggest that AM actions in omental tissues from pregnant subjects are mediated through the AM1 receptor involving CRLR and RAMP2. Involvement of RAMP3 in AM actions in this adipose tissue from pregnant women requires further studies.
In summary, the current study demonstrated that the local AM system in adipocytes might be physiologically important in the metabolic functions of adipose tissue as an autocrine and paracrine organ (Supplemental Fig. 1 ). Excessive AM production by adipose tissues in GDM may stimulate lipolysis through interfering with the insulin signaling cascade as well as increased leptin and resistin production. Increases in circulating lipids and adipokines contribute to the development of GDM and result in altered transport of nutrients to the fetus, thus leading to the fetal excessive adiposity and overgrowth. To our knowledge, our study is the first to illustrate a role for AM in the pathophysiology of GDM, but it is not yet clear whether the induction of adipose tissue AM expression in GDM is a causative or compensatory event of an altered adipocyte function. Lipid dysregulation may be fundamental to the pathobiology of GDM and fetal macrosomia, and the blockage of adipose tissue AM's actions may be a new target of a therapeutic intervention for GDM. 
